Scott Tagawa, Md, Discusses The Results Of Phase I Dose-Escalation Study Regarding Mcrpc

Scott Tagawa, MD, discusses the results of Phase I dose-escalation study regarding mCRPC

Scott Tagawa, MD, shares results of phase 1 dose escalation study of 225Ac-J591 in mPC patients

Phase I/II dose-escalation study of 225Ac-J591 in progressive mCRPC

Phase I dose-escalation study of fractionated dose 225Ac J591 for mCRPC

A phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive mCRPC

The development and results of a dose-intense regimen using 177Lu-PSMA-617 for progressive mCRPC

Results of Phase I Study Reach Primary End Point for mCRPC

Targeted Oncology

PSMA-targeted alpha emitter 225Ac-J591 for mCRPC

Dr. Tagawa on Preliminary Data With 225Ac-J591 in mCRPC

Radionuclide conjugates 225Ac-J591 and 177Lu-PSMA-I&T for mCRPC

Targeting PSMA in mCRPC

PSMA Imaging: VISION Trial with Dr. Scott Tagawa

VISION: 177Lu-PSMA-617 in PSMA-positive mCRPC

Fractionated dose 177Lu-PSMA-617 in patients with mCRPC

Scott Tagawa MD, considers next steps in the development of the PSMA-targeted alpha emitter in mCRPC

Dr. Tagawa Discusses Agents Targeted Against PSMA

Targeted Oncology

Dr. Tagawa on Remaining Questions With PSMA-Targeted Radionuclide Therapy in mCRPC

Scott Tagawa, MD, on promising PSMA products in development for prostate cancer treatment

Scott Tagawa, MD, on PSMA Targeting in Prostate Cancer Treatment

Scott Tagawa, MD, on the Impact of Racial Disparity and COVID-19 on Prostate Cancer Clinical Trials